Dr. Lal PathLabs Ltd
BSE:539524
Relative Value
The Relative Value of one
LALPATHLAB
stock under the Base Case scenario is
1 690.88
INR.
Compared to the current market price of 1 405.95 INR,
Dr. Lal PathLabs Ltd
is
Undervalued by 17%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
LALPATHLAB Competitors Multiples
Dr. Lal PathLabs Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Dr. Lal PathLabs Ltd
BSE:539524
|
235.7B INR | 8.8 | 44.6 | 29.4 | 36.5 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
96.8B USD | 0.2 | 206.9 | 13.7 | 13.7 | |
| US |
|
Cigna Corp
NYSE:CI
|
75.3B USD | 0.3 | 12.3 | 0 | 0 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
61.7B EUR | 0.3 | 11.8 | 7.6 | 9.7 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.3B EUR | 1.2 | 23.9 | 10.5 | 15.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.7B EUR | 1.2 | 32.9 | 10.4 | 22.1 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.1B USD | 1.7 | 27 | 14.5 | 20.2 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.3B USD | 2 | 22.4 | 12.2 | 16.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.8B EUR | 0.6 | 16.3 | 6.4 | 13.7 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.6B USD | 14 | -31.7 | -33.4 | -30.3 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 0.8 | 13.7 | 7.6 | 10.3 |